Polarean’s lung diagnostic to be highlighted by leading researchers
Francesca Morgan
RNS Newswire
07:25, 30th July 2020

Polarean Imaging (AIM: POLX) FOLLOW said a number of presentations highlighting the use of its hyperpolarized Xenon 129 ("129Xe") will be made at the American Thoracic Society and the International Society for Magnetic Resonance in Medicine ("ISMRM") virtual conference.

The medical-imaging technology company said over forty abstracts related to the use of the group’s MRI technology hyperpolarized 129Xe were accepted for presentation at ATS 2020.

The group’s 129Xe MRI technology visualises the small airways and pulmonary gas exchange tissues of the lung, offering a significantly higher functional resolution which is important in detecting early disease and subtle changes in the progression of disease.

Shares in Polarean Imaging have traded strongly over the past three months to open at 31p .

"We are pleased to see 129Xenon in MRI highlighted at these key scientific meetings,” said Richard Hullihen, Chief Executive Officer of Polarean.

He added, “It is a testament to the growing interest in exploring hyperpolarized 129Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases.”

29Xenon can also be used to monitor progression and therapeutic response in the patient.

The groups said the fact that several leading researchers have made use of Polarean's products highlights “the growing academic acceptance of the Company's technology.”

“We hope that the inclusion of so many sessions on 129Xenon will continue to showcase Polarean's important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system,” added Hullihen.

Follow News & Updates from Polarean Imaging: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles